SR
SRNE.US Sorrento Therape
- Market cap
- USD 165K
- P/E
- -
- P/B
- 4.01x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2023.
Is SRNE.US undervalued?
Graham numberThe Graham number of Sorrento Therape cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sorrento Therape fundamental analysis
No fundamental analysis for Sorrento Therape yet.
Sorrento Therape stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sorrento Therape
Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, provides therapeutic solutions in the United States and internationally. It offers chimeric antigen receptor T-cell therapy, dimeric antigen receptor T-cell therapy, and antibody-drug conjugates, as well as Seprehvec, SOFUSA, RTX, and SEMDEXA. The company also develops antiviral therapies and vaccines, including Abivertinib, COVI-MSC, COVI-AMG, COVIDROPS, and COVI SHIELD; and diagnostic t…
Full company profileSorrento Therape financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sorrento Therape annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 460K | 3.83M | 4.59M | 8.15M | 152M | 21.2M | 31.4M | 40.0M | 52.9M | 62.8M | 62.6M |
| Gross Profit | 456K | 1.78M | 2.64M | 7.34M | 148M | 14.1M | 19.2M | 30.0M | 39.9M | 29.4M | 35.3M |
| Operating Income | -21.7M | -34.7M | -74.0M | -96.8M | 25.3M | -150M | -195M | -202M | -368M | -379M | -367M |
| EBITDA | -20.4M | -31.5M | -5.48M | -57.3M | -14.8M | -143M | -183M | -192M | -383M | -365M | -326M |
| Net Income | -21.9M | -34.7M | -45.8M | -60.9M | 9.13M | -204M | -359M | -309M | -429M | -559M | -470M |
| EPS | -1.46 | -1.30 | -1.24 | -1.21 | 0.13 | -1.92 | -2.56 | -1.34 | -1.46 | -1.33 | -0.85 |
| Balance Sheet | |||||||||||
| Total Assets | 92.6M | 142M | 344M | 402M | 432M | 624M | 558M | 536M | 695M | 473M | 457M |
| Total Liabilities | 25.8M | 32.8M | 203M | 315M | 225M | 417M | 525M | 395M | 617M | 495M | 655M |
| Shareholders' Equity | 66.8M | 109M | 141M | 86.5M | 207M | 208M | 32.8M | 141M | 78.1M | -21.7M | -205M |
| Cash & Short-term Investments | 31.7M | 71.9M | 136M | 83.5M | 20.9M | 159M | 22.5M | 56.5M | 127M | 50.0M | 80.6M |
| Total Debt | 4.80M | 12.1M | 9.23M | 47.3M | 5.21M | 233M | 291M | 169M | 238M | 135M | 208M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -16.5M | -28.8M | -42.1M | -70.9M | -99.2M | -112M | -173M | -160M | -282M | -294M | -210M |
| Capital Expenditure | 931K | 591K | 3.71M | 6.86M | 11.0M | 11.2M | 11.4M | 37.6M | 8.87M | 13.7M | 452K |
| Free Cash Flow | -17.4M | -29.4M | -45.8M | -77.8M | -110M | -123M | -184M | -197M | -291M | -308M | -211M |
| Ratios | |||||||||||
| ROE | -32.8% | -31.9% | -32.5% | -70.4% | 4.4% | -98.1% | -1,096.3% | -219.3% | -549.1% | - | - |
| ROA | -23.7% | -24.5% | -13.3% | -15.2% | 2.1% | -32.6% | -64.4% | -57.6% | -61.7% | -118.3% | -102.8% |
| Net Profit Margin | -4,761.8% | -906.1% | -998.1% | -747.3% | 6.0% | -960.4% | -1,142.5% | -771.7% | -810.9% | -890.1% | -750.8% |
| Debt to Equity | 0.07x | 0.11x | 0.07x | 0.55x | 0.03x | 1.12x | 8.88x | 1.20x | 3.04x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Sorrento Therape dividends
Sorrento Therape has not paid dividends in the last 9 fiscal years.
Last stock split: 1:25 on Aug 1, 2013.
Who owns Sorrento Therape
- Insiders 0.00%
- Institutions 0.02%
- Public & others 99.98%
- Shares outstanding 551M
- Free float 539M
Top funds holding SRNE.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Belfund SICAV Belinvest Equity A USD Acc | 110K | 0.02% | 0.00% | Aug 2024 |
| AVIP BlackRock Advtg Small Cp Gr Prtfl | 45.2K | 0.01% | 0.00% | Jun 2024 |
| BNYM Mellon SL Market Completion UC1 | 20.7K | 0.00% | +0.11% | Sep 2024 |
| Guggenheim Active Allocation Fund | 3.48K | 0.00% | 0.00% | May 2024 |
| BNYM Mellon AFLCIO SL Brd Mkt Index Inst | 1.92K | 0.00% | 0.00% | Sep 2024 |
| BNYM Mellon NSL Smid Cap Stck Index Inst | 1.90K | 0.00% | 0.00% | Sep 2024 |
| BNYM Mellon DB NSL Small Cap Stock Index | 1.70K | 0.00% | -3.74% | Sep 2024 |
| ZWJ Equity | 800.00 | 0.00% | 0.00% | Jun 2024 |
| BNYM Mellon NSL Mkt Completion Fund Inst | 765.00 | 0.00% | -1.03% | Sep 2024 |
| BNYM Mellon NSL Broad Market SIF Instl | 4.00 | 0.00% | 0.00% | Sep 2024 |
Top institutions holding SRNE.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Lattice Capital Management LLC | 51.8K | 0.01% | 0.00% | Jun 2024 |
| Kitzinger Lautmann Capital Mgmt Inc | 30.0K | 0.01% | 0.00% | Jun 2024 |
| SlateStone Wealth, LLC | 21.4K | 0.00% | 0.00% | Jun 2024 |
| Huntington National Bank | 5.00K | 0.00% | 0.00% | Jun 2024 |
| AlphaMark Advisors, LLC | 2.14K | 0.00% | 0.00% | Jun 2024 |
| ARGI Investment Services, LLC | 0.00 | 0.00% | -100.00% | Jun 2024 |
| Federation des caisses Desjardins du Quebec | 0.00 | 0.00% | -100.00% | Jun 2024 |
Sorrento Therape company profile
- Company name
- Sorrento Therape
- Ticker
- SRNE.US
- Exchange
- USA Stocks
- Listed since
- Jan 11, 2010
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 949
- Fiscal year end
- December
- Address
- 4955 Directors Place, San Diego, CA, United States, 92121
- Phone
- 858 203 4100
- Website
- sorrentotherapeutics.com
About Sorrento Therape
Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, provides therapeutic solutions in the United States and internationally. It offers chimeric antigen receptor T-cell therapy, dimeric antigen receptor T-cell therapy, and antibody-drug conjugates, as well as Seprehvec, SOFUSA, RTX, and SEMDEXA. The company also develops antiviral therapies and vaccines, including Abivertinib, COVI-MSC, COVI-AMG, COVIDROPS, and COVI SHIELD; and diagnostic test solutions, such as COVISTIX, COVITRACK, and Virex. Its products are used for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases treatment. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.
Sorrento Therape management
2- Dr. Henry H. Ji Ph.D.Chairman, President & CEO · born 1964
- Dr. Scott Schaus Ph.D.Chief Technology Officer